Original article
Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis☆

https://doi.org/10.1016/0091-6749(92)90131-KGet rights and content

Abstract

Immunoblotting, radioallergosorbent test (RAST), and enzyme-linked immunosorbent assay (ELISA) were performed to determine specific IgE and IgG responses to Aspergillus fumigatus (Af) allergens (IgE-Af; IgG-Af). Serology results were compared in patients with allergic bronchopulmonary aspergillosis (ABPA) (n = 43), patients with Aspergillus fumigatus-associated asthma (Af-asthma) (n = 26), and healthy individuals (n = 3). In patients with different clinical phases of ABPA, three specific immunopatterns were found by immunoblotting. It is proposed to classify ABPA into the active, intermediate, and remission phase with respect to the specific immunoresponse to Af-allergens and asthma symptoms. First, the active phase of ABPA is characterized by a fully developed specific immunoresponse to Af-allergens and severe asthma. Second, the intermediate phase includes patients with elevated specific immunologic findings without asthma symptoms. Third, the remission phase is characterized by a weak specific immunoresponse to Af-allergens after a long-term asymptomatic period. No correlation occurred between specific immunopatterns and irreversible bronchopulmonary lesions. The IgE-Af RAST and IgG-Af ELISA titers of patients with ABPA in the active and intermediate phase were significantly higher compared with patients with ABPA in remission phase and with patients with Af-asthma. In particular, the demonstration of positive IgG-Af ELISA titer generally allows the serologic discrimination of patients with asthma and ABPA from patients with Af-asthma in clinical practice. The present study revealed that immunoblots of most patients with Af-asthma were negative. Immunoblotting demonstrated an IgG reactivity exclusively to low molecular weight (MW) Af-allergens in 8 out of 26 patients with Af-asthma and in the three healthy individuals, and this IgG response may reflect naturally occurring antibodies.

References (43)

  • DC Currie et al.

    Comparison of narrow section computed tomography and plain chest radiography in chronic allergic bronchopulmonary aspergillosis

    Clin Radiol

    (1987)
  • EJ Bardana et al.

    The primary interaction of antibody to components of aspergilli

    J Allergy Clin Immunol

    (1972)
  • KFW Hinson et al.

    Bronchopulmonary aspergillosis: a review and a report of eight new cases

    Thorax

    (1952)
  • EJ Bardana

    The clinical spectrum of aspergillosis: part 2: classification and description of saprophytic, allergic and invasive variants of human disease

    CRC Crit Rev Clin Lab Sci

    (1980)
  • DS McCarthy et al.

    Allergic bronchopulmonary aspergillosis: clinical immunology: 1 clinical features

    Clin Allergy

    (1971)
  • BH Safirstein et al.

    Five-year follow-up of allergic bronchopulmonary aspergillosis

    Am Rev Respir Dis

    (1973)
  • RA Mintzer et al.

    The spectrum of radiologic findings in allergic bronchopulmonary aspergillosis

    Diagn Radiol

    (1978)
  • PA Greenberger et al.

    Allergic bronchopulmonary aspergillosis: model of bronchopulmonary disease with defined serological, radiological pathologic and clinical findings from asthma to fatal destructive lung

    Chest

    (1987)
  • DS McCarthy et al.

    Allergic bronchopulmonary aspergillosis: clinical immunology: 2 skin nasal and bronchial tests

    Clin Allergy

    (1971)
  • KJ Turner et al.

    The association of lung shadowing with hypersensitivity responses in patients with allergic bronchopulmonary aspergillosis

    Clin Allergy

    (1974)
  • CE Arbesmann et al.

    IgE antibodies in sera of patients with allergic bronchopulmonary aspergillosis

    Clin Allergy

    (1974)

    • Cited by (58)

    • Allergic bronchopulmonary aspergillosis

      2009, Chest
      Citation Excerpt :

      After treatment with glucocorticoids, the serum IgE levels decline, and a 35 to 50% decrease is taken as a criteria for remission.79 The serum IgE determination is also used for follow-up, and a doubling of the patient's baseline IgE levels indicates relapse of ABPA.80,81 An elevated level of A fumigatus-specific antibodies measured by fluorescent enzyme immunoassay is considered the hallmark of ABPA.22

    • Allergy diagnostic testing: An updated practice parameter

      2008, Annals of Allergy, Asthma and Immunology

    • Allergic Bronchopulmonary Aspergillosis

      2008, Pediatric Respiratory Medicine

    • Antifungal therapy for allergic bronchopulmonary aspergillosis

      2003, Journal of Allergy and Clinical Immunology

    • Allergologic diagnostics in bronchiectasis

      2023, Atemwegs- und Lungenkrankheiten

    • Allergic bronchopulmonal aspergillosis

      2022, Padiatrische Praxis
    View all citing articles on Scopus
    ☆

    Presented in part at the Annual Meeting of the European Academy of Allergology and Clinical Immunology (EAACI), Berlin 1989.

    1

    From the Hochgebirgsklinik Davos-Wolfgang, Asthma- and Allergy Clinic, Davos-Wolfgang, Switzerland.

    a

    From the Department of Allergology, Clinic for Internal Medicine, State University Hospital, Groningen, The Netherlands.

    View full text
    Copyright © 1992 Published by Mosby, Inc.